132 related articles for article (PubMed ID: 38520088)
1. EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer.
Huang J; Yin Q; Wang Y; Zhou X; Guo Y; Tang Y; Cheng R; Yu X; Zhang J; Huang C; Huang Z; Zhang J; Guo Z; Huo X; Sun Y; Li Y; Wang H; Yang J; Xue L
Adv Sci (Weinh); 2024 Jun; 11(23):e2308045. PubMed ID: 38520088
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
3. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
4. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
5. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
[TBL] [Abstract][Full Text] [Related]
6. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.
Huang X; Zhang Q; Lou Y; Wang J; Zhao X; Wang L; Zhang X; Li S; Zhao Y; Chen Q; Liang T; Bai X
Cancer Immunol Res; 2019 Oct; 7(10):1580-1590. PubMed ID: 31399419
[TBL] [Abstract][Full Text] [Related]
7. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer.
Li N; Geng F; Liang SM; Qin X
Cell Signal; 2022 Aug; 96():110351. PubMed ID: 35523402
[TBL] [Abstract][Full Text] [Related]
8. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
9. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
[TBL] [Abstract][Full Text] [Related]
10. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
[TBL] [Abstract][Full Text] [Related]
11. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
12. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
13. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
[TBL] [Abstract][Full Text] [Related]
14. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
[TBL] [Abstract][Full Text] [Related]
15. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
16. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
17. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway.
Wang Z; Guo Z; Wang X; Liao H; Chai Y; Wang Z; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552722
[TBL] [Abstract][Full Text] [Related]
19. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
20. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
Jingjing W; Wenzheng G; Donghua W; Guangyu H; Aiping Z; Wenjuan W
Cancer Med; 2018 Aug; 7(8):4004-4011. PubMed ID: 29992764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]